Xenetic Biosciences, Inc.
NASDAQ Capital MarketTotal Valuation
Xenetic Biosciences, Inc. carries a market capitalization of 5.10M, placing it among publicly traded companies globally. Its enterprise value stands at -2.54M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5.10M |
| Enterprise Value | -2.54M |
Share Statistics
Xenetic Biosciences, Inc. currently has 2.29M shares outstanding.
| Shares Outstanding | 2.29M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 1.51, and the price-to-book ratio stands at -0.02.
| PE Ratio | N/A |
| PS Ratio | 1.51 |
| PB Ratio | -0.02 |
| P/TBV Ratio | 0.69 |
| P/FCF Ratio | -2.64 |
| P/OCF Ratio | -2.64 |
Enterprise Valuation
| EV / Sales | 0.77 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Xenetic Biosciences, Inc. maintains a current ratio of 7.93, meaning it holds 7.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 7.93 |
| Quick Ratio | 7.67 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -32.61 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Xenetic Biosciences, Inc.'s stock has declined approximately -24.36975% over the past 52 weeks. The 50-day moving average sits at 2.99, while the 200-day moving average is 2.91.
| Beta (5Y) | N/A |
| 52-Week Price Change | -24.36975% |
| 50-Day Moving Average | 2.99 |
| 200-Day Moving Average | 2.91 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Xenetic Biosciences, Inc. generated 3.19M in revenue and converted that into -2.23M in net income, yielding earnings per share of -1.25. EBITDA reached -2.39M, while operating income came in at -2.39M.
| Revenue | 3.19M |
| Gross Profit | N/A |
| Operating Income | -2.39M |
| Pretax Income | -2.23M |
| Net Income | -2.23M |
| EBITDA | -2.39M |
| EBIT | -2.39M |
| Earnings Per Share (EPS) | -1.25 |
Balance Sheet
Total book value stands at -200.33M, with working capital of 6.64M providing operational flexibility.
| Cash & Cash Equivalents | 7.35M |
| Total Debt | N/A |
| Net Debt | -7.35M |
| Equity (Book Value) | -200.33M |
| Book Value Per Share | -111.80 |
| Working Capital | 6.64M |
Cash Flow
Xenetic Biosciences, Inc. produced -1.82M in operating cash flow over the past twelve months.
| Operating Cash Flow | -1.82M |
| Capital Expenditures | N/A |
| Free Cash Flow | -1.82M |
| FCF Per Share | -1.02 |
Margins
Xenetic Biosciences, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -75.05 and net profit margin of -70.03 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -75.05 |
| Pretax Margin | -70.03 |
| Profit Margin | -70.03 |
| EBITDA Margin | -75.05 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | N/A |
| FCF Yield | -37.92 |
Stock Splits
Xenetic Biosciences, Inc.'s most recent stock split took place on May 15, 2023 with a 10:1 split ratio.
| Last Split Date | 5/15/2023 |
| Split Ratio | 10:1 |
Scores
Xenetic Biosciences, Inc. posts an Altman Z-Score of -32.04, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -32.04 |